Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Coagulation profile of sickle cell patients with leg ulcers
source: American Society of Hematology
year: 2018
authors: Ugochi Olivia Ogu, Ashley Buscetta, Elena Crouch, Shuo You, Christopher Bradford, Moonseong Heo, Khadijah Abdallah, Giacomo Vinces, Vence L. Bonham, Caterina Minniti
summary/abstract:Leg ulcers are a serious complication of Sickle Cell Disease (SCD), often linked to a hemolytic phenotype that includes priapism, pulmonary hypertension (PH) and renal disease. In the SCD pathogenesis, hemolysis and ischemia-reperfusion injuries lead to white blood cell (WBC), platelet and endothelial cell activation, pro-inflammatory cytokine production and subsequent activation of coagulation that tips the balance towards a prothrombotic and inflammatory state. Decreased levels of the naturally occurring anticoagulants (NOACs): protein C (PC), protein S (PS), antithrombin III (ATIII), have been observed in patients with SCD in steady state, with some reports stating no differences between steady state and crisis. This occurs due to decreased production, increased consumption, or a combination of both. However, the definite mechanisms have not yet been elucidated. Factor V Leiden (FVL) and prothrombin G20210A mutations are rare in African Americans and in patients with SCD. We speculated that patients with leg ulcers would have a more pronounced pro-thrombotic phenotype than patients who never developed them.
Conclusions: In SCD patients with leg ulcers, PC and PS levels are significantly lower than in SCD patients without leg ulcers. Additionally, in SCD patients with leg ulcers, there is a trend towards decreased levels of AT III and increased LA positivity. FVL and prothrombin gene mutations were rare in our cohort, consistent with the general population. The above findings did not correlate clinically with a history of DVT/PE in the same population.
Our results of decreased NOACs confirm previous reports from our group that demonstrated similar findings. Of greater significance, however, is our finding that sickle cell patients with leg ulcers have further decreased levels of the NOACs compared to their counterparts without leg ulcers. This finding lends credence to the hypothesis that sickle cell patients with leg ulcers have a procoagulant phenotype (Am J Hematol. 2011 Aug; 86: 705–8, Am J Hematol. 2014 Jan; 89: 1–6). Whether this translates to an increased risk of thromboembolic events remains uncertain. From our findings, it may not be the case for DVTs and PEs. However, further studies evaluating other clinical manifestations such as priapism, PH, stroke, avascular necrosis, and retinopathy, are still needed. Future directions include further correlation with the above-mentioned manifestations to provide a more comprehensive picture.
organization: Montefiore Medical Center, USA; National Institutes of Health, USA; Albert Einstein College Of Medicine, USA; Montefiore Medical Center, USADOI: 10.1182/blood-2018-99-113184
read more
+myBinderRelated Content
-
The psychosocial impact of leg ulcers in patients with sickle cell disease: I don’t want them to know my littl...BACKGROUND: Sickle cell disease (SCD) i...
-
Sickle Cell Disease: A Review of Nonpharmacological Approaches for PainCONTEXT: Sickle cell disease (SCD) is a...
-
Living With Sickle Cell Disease Is a Constant Battle With Pain, According to one Woman Who Has It“You don’t look sick.” That’s ...
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
Today’s Faces of Sickle Cell Disease: Jennelle StephensonJennelle Stephenson was diagnosed with S...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study FindsHydroxyurea, a treatment recommended for...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.